Platelet Function Testing in Target Safety Assessments Adverse Findings Adverse findings in non-clinical safety/toxicity testing continue to be a major reason for failure and/or complexity in drug projects. Since primary target-related toxicity plays a role in a significant proportion of these failures, an in-depth assessment of potential adverse consequences [...]
Unravelling Some Mechanistic and Clinical Aspects of Immunological Drug-Drug Interactions Dr Sean Hammond, as a member of an interdisciplinary team, has recently published the third of a series of papers seeking to unravel mechanistic and clinical aspects of the immunological drug-drug interactions that occur with immune checkpoint inhibitors. Immunotoxicology [...]
ApconiX Is Recruiting a Target Safety Biologist The closing date for this job vacancy has passed. Please visit our Come and Join Us page for current vacancies. If you believe you have the skills and experience and would like to become part of our team please send your speculative CV to careers@apconix.com ApconiX [...]
SOT 2022 - Continuous Education Course Professor Ruth Roberts will be presenting at the SOT 2022 Continuous Education (CE) Programme Course in the session entitled ‘Safety Evaluation Strategies in Drug Discovery: From Target Assessment to Identification of Drug Candidates’. This CE course will take a chronological look at drug [...]
Acuity Target Safety Assessments: Knowledge is Power A thorough understanding of potential target-related effects is crucial to making the right choices in drug discovery. Experienced project toxicologists extract and interpret data from mouse knockouts, human gene mutations and known effects of modulators to determine the potential consequences of target inhibition or [...]
ApconiX Are in Boston, USA at the End of August Dr Richard Knight and Professor Ruth Roberts are travelling to Boston at the end of August to meet with old colleagues and new contacts, promoting the company’s services in Project Toxicology, Ion Channel Screening and Assay Development, Target Safety [...]
ApconiX Welcomes Dr Russell Huby to the Team. ApconiX is delighted to welcome Dr Russell Huby to the team. Russell joins the team of experts in nonclinical safety toxicology at ApconiX and will be primarily working in the area of target safety assessments. Russell graduated from the University of [...]
Successful DMDG Symposium at Alderley Park The DMDG Symposium at Alderley Park was a great success. Organised by the teams from Sygnature, Alderley Park and ApconiX, over 120 delegates from around the country joined the symposium Dx Toxicology: Strategies for Success in Discovery and Development, focusing on asking the [...]
ApconiX is excited to announce the opening of our new office in Sweden. The subsidiary ApconiX AB will be located at AstraZeneca’s BioVentureHub in Gothenburg. ApconiX was formed by Dr Richard Knight, Dr Michael Morton and Professor Ruth Roberts in 2015 and is based at Alderley Park in Cheshire, U.K. The co-founders have established a [...]
ApconiX is delighted to welcome Dr Karin Burnett, an experienced project toxicologist with a broad knowledge of toxicology and chemical risk assessment in the pharmaceutical industry. Karin will join the team of experts in nonclinical safety toxicology at ApconiX, who cover all major safety disciplines and are committed to advancing the science of drug safety. Karin [...]
